For the Psychiatrist - Reference

Anderson GM. Comments on "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression." J Clin Psychopharmacol. 1996;16:256.

Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996;19:378-383.

Artigas F. Pindolol, 5-hydroxytryptamine, and antidepressant augmentation. Arch Gen Psychiatry. 1995;52:969-970.

Artigas F, Perez V, Alvarez, E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51:248-251.

Atack JR, Broughton HB, Pollack SJ. Inositol monophosphatase (a putative target for Li+ in the treatment of bipolar disorder. TINS. 1995;18:343-349.

Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry. 1991;36:749-750.

Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH. Inositol treatment in psychiatry. Psychopharmacol Bull. 1995;31:167-175.

Blier P, Bergeron R. "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.î J Clin Psychopharmacol. 1995;15:217-222.

Blier P, Bergeron R, Hebert C. Differential effectiveness of pindolol addititon in treatment-resistant obessive-compulsive disorder and depression. Psychopharmacol Bull. 1995;31:555.

Bridges PK, Hodgkiss AD, Malizia AL. Practical management of treatment-resistant affective disorders. Br J Hosp Med. 1995;54:501-506.

Cadieux RJ. Azapirones: an alternative to benzodiazepines for anxiety. Am Fam Phys. 1996;53:2349-2353.

Dimitriou EC. Augmenting the effects of antidepressant medication by adding buspirone. Poster presentation, Psychiatric World Congress, Madrid, Spain. August, 1996.

Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995;56:52-55.

Glennon RA, Dukat M. Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth Generation of Progress. New York, NY: Raven Press Ltd; 1995:415-430.

Hyman SE, Arana GW, Rosenbaum JF. Handbook of Psychiatric Drug Therapy, 3rd ed. Boston, Mass:Little, Brown and Company;1995:43-92.

Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217-220.

Joffe RT, Levitt AJ, Sokolov STH. Augmentation strategies: focus on anxiolytics. J Clin Psychiatry. 1996;57(suppl 7):25-31.

Joffe RT, Levitt AJ. Antidepressant failure: augmentation and substitution. J Psychiatry & Neuroscience. 1995;20:7-9.

Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54:269-271.

Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387-393.

Joffe RT. Triiodothryonine potentiation of fluoxetine in depressed patients. Can J Psychiatry. 1992;37:48-50.

Joffe RT, Singer W. A comparison of triiodothryonine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Research. 1990; 32:241-251.

Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. Double-blind, controlled trial of inositol treatment of depression. Hm J Psychiatry. 1995;152:792-794.

Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth Generation of Progress. New York, NY: Raven Press Ltd; 1995:933-944.

de Montigny C. Lithium addition in treatment-resistant depression. International Clinical Psychopharmacology. 1994;9(suppl):31-35.

Murphy DL, Mitchell PB, Potter WZ. Novel pharmacological approaches to the treatment of depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth Generation of Progress. New York, NY: Raven Press Ltd; 1995:1143-1154.

Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry. 1994;55:20-26.

Robillard M, Lieff S. Augmentation of antidepressant therapy by buspirone: three geriatric case histories. Can J Psychiatry. 1995;40:639-640.

Robinson DS, Rickels K, Feighner J, et al. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol. 1990;10:67S-76S.

Shih JC, Chen K J-S, Gallaher TK. Molecular biology of serotonin receptors: a basis for understanding and addressing brain function. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth Generation of Progress. New York, NY: Raven Press Ltd; 1995:407-414.

Sussman N. Neurochemistry of serotonin and depression. Primary Psychiatry. 1995;3:28-33.

Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry. 1994;12:3-21.

Stahl SM. Essential Psychopharmacology. Cambridge, MA: Cambridge University Press; 1996.

Thase ME, Rush JA. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth Generation of Progress. New York, NY: Raven Press Ltd; 1995:1081-1097.